Opendata, web and dolomites

NANOELAST SIGNED

Next-Generation Urinary Catheters for Preventing Catheter Associated Urinary Tract Infections: Emphasis on Antibiotic Resistance

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NANOELAST project word cloud

Explore the words cloud of the NANOELAST project. It provides you a very rough idea of what is the project "NANOELAST" about.

ageing    caused    biofilm    human    patients    cauti    prevents    saving    usd    made    conventional    difficult    risk    device    onto    harm    reduce    surface    generation    urinary    threatening    bacterial    antibiotics    infections    million    treating    indwelling    prevention    antibacterial    special    life    cells    patented    polymer    anti    resistance    complication    advantage    retention    material    resistant    prolonged    nanoelast    killing    societal    faster    elastomeric    extremely    exists    antibiotic    medical    homes    recovery    globally    threat    prophylactic    patient    nearly    ab    incontinence    mortalities    care    tract    mesoporous    amphiphilic    treat    bacteria    causing    amferia    contact    proven    catheters    leads    led    exceed    stays    advantages    hospital    cautis    mainly    catheter    nursing    preventive    longer    kill    attachment    40    global    relieve    hospitals    economic    disturbingly    community    infection    function    infective    responsible    population    ill    prevent   

Project "NANOELAST" data sheet

The following table provides information about the project.

Coordinator
AMFERIA AB 

Organization address
address: PEPPAREDSLEDEN 1
city: Mölndal
postcode: 431 83
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AMFERIA AB SE (Mölndal) coordinator 50˙000.00

Map

 Project objective

Indwelling urinary catheters are life-saving medical devices that are widely used in hospitals and nursing homes to relieve a patient from urinary retention and incontinence. However, prolonged use of these catheters in the urinary tract leads to a life-threatening and disturbingly common complication, called catheter associated urinary tract infection (CAUTI). CAUTIs are mainly caused by bacteria and affect nearly 10 million patients every year globally. This makes CAUTI responsible for 40% of all hospital associated infections and the costs for treating these infections exceed 100 million USD a year. Furthermore, the global threat of antibiotic resistance has made it extremely difficult to treat CAUTI via conventional antibiotics and has led to longer hospital stays for the patient and higher mortalities, especially among the ageing population. A strong need exists for new anti-infective catheters that can prevent CAUTIs by enabling a new function that prevents bacterial attachment onto the catheter surface. Such a device w ill offer several advantages such as, prevention of infections, reduced usage of prophylactic antibiotics, reduced risk of antibiotic resistant infections and faster recovery for the patient. A societal advantage of such an improved anti-infective catheter is the ability to control the rise of antibiotic resistant infections in the hospital and the community and reduce economic impact. Amferia AB has developed and patented a novel amphiphilic antibacterial material-a mesoporous elastomeric polymer, referred to as NANOELAST, that is able to target and kill bacteria rapidly upon contact. Of special interest is that the material has been proven very effective in killing numerous antibiotic resistant bacteria, prevent biofilm formation and without causing any harm to human cells. Amferia aims to evaluate the NANOELAST as the next generation urinary catheter for infection preventive care.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NANOELAST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NANOELAST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

INDEXAR (2020)

DEVELOPING A SCALABLE MOBILE AR BROWSER

Read More